Biogen Inc vs NetApp Inc. — how do they compare? Biogen Inc trades at $191.89 (market cap $30.86B), while NetApp Inc. trades at $175.55 (market cap $32.12B). The key difference: Biogen Inc and NetApp Inc. are close in size by market cap, and NetApp Inc. pays a 1.27% dividend while Biogen Inc pays none. Which is the better fit depends on your goals.
| BIIB | NTAP | |
|---|---|---|
Market Cap | $30.86B | $32.12B |
Sector | Health | Technology |
52-Week High | $216.63 | $181.08 |
52-Week Low | $122.68 | $94.11 |
Enterprise Value | $33.14B | $31.27B |
Dividend Yield | — | 1.27% |
Trailing returns across standard periods
Latest headlines on both assets
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel MS drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is co-promoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with SOBI) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and has launched Spinraza with partner Ionis. Aduhelm was approved as the firm's first Alzheimer's disease therapy in June 2021.
Read more on BIIB →NetApp is a leading provider of enterprise data management and storage solutions. The company's three operating business units are products, software maintenance, and hardware maintenance. NetApp transitioned from a data center storage firm to a company with software data management solutions for multicloud environments. The California-headquartered company sells globally and has approximately 10,000 employees.
Read more on NTAP →